Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

E-ISSN： 1552-4604|53|9|885-891

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.53, Iss.9, 2013-09, pp. : 885-891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Iron Chelation with Deferasirox in Two Patients with HFE Hemochromatosis and Chronic Anemia

Acta Haematologica, Vol. 126, Iss. 2, 2011-06 ,pp. : 119-121

Karger

Access to resources Recommend Favorite

Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia

Acta Haematologica, Vol. 129, Iss. 2, 2012-11 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

Deferasirox (Exjade®) for the Treatment of Iron Overload

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 165-173

Karger

Access to resources Recommend Favorite

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom

By Karnon J. Tolley K. Oyee J. Jewitt K. Ossa D. Akehurst R.

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1609-1621

Informa Healthcare

Access to resources Recommend Favorite

Deferasirox for iron chelation in multitransfused children with sickle cell disease; long‐term experience in the East London clinical haemoglobinopathy network

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 336-342

John Wiley & Sons Inc

Access to resources Recommend Favorite